乙酰半胱氨酸联合布地奈德雾化吸入治疗慢性阻塞性肺疾病急性加重期患者的效果

Effects of Acetylcysteine combined with Budesonide aerosol inhalation in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease

目的:观察乙酰半胱氨酸联合布地奈德雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)患者的效果。方法:回顾性分析2022年1月至2023年5月该院收治的86例AECOPD患者的临床资料,根据治疗方法不同将其分为观察组(n=43)和对照组(n=43)。对照组给予布地奈德雾化吸入治疗,观察组在对照组基础上联合乙酰半胱氨酸雾化吸入治疗,比较两组临床疗效,治疗前后肺功能指标[呼气峰值流速(PEF)、用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))]、炎性指标[白细胞介素-4(IL-4)、肿瘤坏死因子-α(TNF-α)、嗜酸性粒细胞(EOS)]水平,以及治疗期间不良反应发生率。结果:观察组治疗总有效率为93.02%(40/43),高于对照组的76.74%(33/43),差异有统计学意义(P<0.05);治疗后,观察组FVC、FEV_(1)、PEF水平均高于对照组,差异有统计学意义(P<0.05);治疗后,观察组EOS、TNF-α、IL-4水平均低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:乙酰半胱氨酸联合布地奈德雾化吸入治疗AECOPD患者可提高治疗总有效率和肺功能指标水平,降低炎性指标水平,效果优于单纯布地奈德雾化吸入治疗。

Objective:To observe effects of Acetylcysteine combined with Budesonide aerosol inhalation in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:The clinical data of 86 patients with AECOPD admitted to this hospital from January 2022 to May 2023 were retrospectively analyzed.According to different treatment methods,they were divided into observation group(n=43)and control group(n=43).The control group was treated with Budesonide aerosol inhalation,while the observation group was treated with Acetylcysteine aerosol inhalation on the basis of that of the control group.The clinical efficacy,the lung function indexes[peak expiratoryflow(PEF),forced vital capacity(FVC),forced expiratory volume in one second(FEV_(1))]levels,the inflammatory indexes[interleukin-4(IL-4),tumor necrosis factor-α(TNF-α),eosinophil(EOS)]levels before and after the treatment,and the incidence of adverse reactions during treatment were compared between the two groups.Results:The total effective rate of the observation group was 93.02%(40/43),which was higher than 76.74%(33/43)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of FVC,FEV_(1) and PEF in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of EOS,TNF-αand IL-4 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Acetylcysteine combined with Budesonide aerosol inhalation in the treatment of the AECOPD patients can improve the total effective rate of treatment and the levels of lung function indexes,and reduce the levels of inflammatory indicators.Moreover,it is superior to simple Budesonide aerosol inhalation treatment.